Elsilimomab

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Elsilimomab (also known as B-E8) is a mouse monoclonal antibody. B-E8 was developed by Diaclone, a French company which produces many mouse monoclonal antibodies. It (OPR-003) targets (and blocks) Interleukin-6. It has undergone a number of early stage clinical trials, e.g. for lymphoma and myeloma. It was used as a template to develop a high-affinity, antagonist, fully human anti-IL-6 mAb 1339.

Elsilimomab (also known as B-E8) is a mouse monoclonal antibody. B-E8 was developed by Diaclone, a French company which produces many mouse monoclonal antibodies. It (OPR-003) targets (and blocks) Interleukin-6. It has undergone a number of early stage clinical trials, e.g. for lymphoma and myeloma. It was used as a template to develop a high-affinity, antagonist, fully human anti-IL-6 mAb 1339.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1157644829 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

4 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.